Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VYNE 
Vyne Therapeutics Inc (VYNE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: VYNE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.99% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.25M USD | Price to earnings Ratio 1.74 | 1Y Target Price 5.58 |
Price to earnings Ratio 1.74 | 1Y Target Price 5.58 | ||
Volume (30-day avg) 132976 | Beta 1.35 | 52 Weeks Range 1.53 - 4.30 | Updated Date 03/30/2025 |
52 Weeks Range 1.53 - 4.30 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5250.51% |
Management Effectiveness
Return on Assets (TTM) -34.54% | Return on Equity (TTM) -60.47% |
Valuation
Trailing PE 1.74 | Forward PE - | Enterprise Value -38145912 | Price to Sales(TTM) 46.45 |
Enterprise Value -38145912 | Price to Sales(TTM) 46.45 | ||
Enterprise Value to Revenue 10.04 | Enterprise Value to EBITDA 1.84 | Shares Outstanding 14749400 | Shares Floating 10069856 |
Shares Outstanding 14749400 | Shares Floating 10069856 | ||
Percent Insiders 8.32 | Percent Institutions 56.03 |
Analyst Ratings
Rating 4.75 | Target Price 5.58 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vyne Therapeutics Inc
Company Overview
History and Background
Vyne Therapeutics Inc., formerly known as Foamix Pharmaceuticals Ltd., is a pharmaceutical company focused on developing and commercializing innovative therapeutics for dermatology. It was founded in 2003. Significant milestones include FDA approvals for AMZEEQ and ZILXI and the subsequent acquisition by Menlo Therapeutics in 2020. The company was renamed Vyne Therapeutics Inc.
Core Business Areas
- Dermatology: Develops and commercializes therapeutics for dermatological conditions. Focus on acne and rosacea treatments.
Leadership and Structure
The leadership team consists of individuals with experience in pharmaceutical development and commercialization. The organizational structure includes departments for R&D, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- AMZEEQ: A topical minocycline foam indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Market share data is not publicly available in precise numbers. Competitors include other topical acne treatments from companies like Galderma (Differin), Bausch Health (Duobrii), and numerous generic products.
- ZILXI: A topical minocycline foam indicated for the treatment of inflammatory lesions of rosacea in adults. Market share data is not publicly available in precise numbers. Competitors include other topical rosacea treatments from companies like Galderma (Oracea, Soolantra), and various generic formulations.
Market Dynamics
Industry Overview
The dermatology market is characterized by ongoing research and development of treatments for various skin conditions, including acne, rosacea, psoriasis, and eczema. There is increasing demand for innovative therapies.
Positioning
Vyne Therapeutics is positioned as a company focused on providing innovative topical minocycline treatments. Its competitive advantage lies in its foam-based drug delivery technology.
Total Addressable Market (TAM)
The global dermatology market is estimated to be worth billions of dollars. Vyne Therapeutics' TAM is a subset of this, focusing on the acne and rosacea segments. Their positioning allows them to target a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary foam-based drug delivery technology
- FDA-approved products (AMZEEQ and ZILXI)
- Focus on specific dermatological conditions
- Experienced leadership team
Weaknesses
- Limited product portfolio
- Reliance on a single active ingredient (minocycline)
- Competition from established players with broader portfolios
- Financial performance depends on the successful commercialization of existing products
Opportunities
- Expanding indications for existing products
- Developing new dermatological therapies
- Strategic partnerships and acquisitions
- Geographic expansion
Threats
- Competition from generic drugs
- Regulatory hurdles and potential setbacks
- Changes in healthcare reimbursement policies
- Adverse events or safety concerns related to products
Competitors and Market Share
Key Competitors
- GILD
- BHC
- LEO
Competitive Landscape
Vyne Therapeutics faces competition from established pharmaceutical companies with broader portfolios and greater resources. Its competitive advantage lies in its unique drug delivery technology.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been influenced by product approvals, commercialization efforts, and strategic decisions.
Future Projections: Future growth projections are based on analyst estimates and the company's own guidance.
Recent Initiatives: Recent initiatives include focusing on commercial execution and exploring new product development opportunities.
Summary
Vyne Therapeutics is a pharmaceutical company specializing in dermatology. They have FDA-approved products but a limited portfolio. Future success depends on commercial execution and new product development. Intense competition within the industry is a significant hurdle.
Similar Companies
BHC
Bausch Health Companies Inc
BHC
Bausch Health Companies Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
LEO
BNY Mellon Strategic Municipals Inc
LEO
BNY Mellon Strategic Municipals Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vyne Therapeutics Inc
Exchange NASDAQ | Headquaters Bridgewater, NJ, United States | ||
IPO Launch date 2018-01-25 | CEO, President & Director Mr. David T. Domzalski | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://vynetherapeutics.com |
Full time employees 13 | Website https://vynetherapeutics.com | ||
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of chronic inflammatory and immune-mediated conditions. Its lead program, repibresib gel (VYN201), is a topically administered small molecule pan bromodomain (BD) extra-terminal (BET) inhibitor soft drug that address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. The company also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.